Biocept, Inc.
BIOC
$2.05
-$0.11-5.09%
| Weiss Ratings | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.00 | |||
| Price History | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -58.50% | |||
| 30-Day Total Return | -80.82% | |||
| 60-Day Total Return | -85.17% | |||
| 90-Day Total Return | -88.56% | |||
| Year to Date Total Return | -87.58% | |||
| 1-Year Total Return | -95.05% | |||
| 2-Year Total Return | -98.44% | |||
| 3-Year Total Return | -98.40% | |||
| 5-Year Total Return | -99.89% | |||
| 52-Week High % Change | -95.47% | |||
| 52-Week Low % Change | 8.54% | |||
| Price | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $47.70 | |||
| 52-Week Low Price | $1.99 | |||
| 52-Week Low Price (Date) | May 31, 2023 | |||
| 52-Week High Price (Date) | Jun 07, 2022 | |||
| Valuation | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $3.17M | |||
| Enterprise Value | 7.98M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -64.21 | |||
| Earnings Per Share Growth | 338.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.19 | |||
| Price/Book (Q) | 0.53 | |||
| Enterprise Value/Revenue (TTM) | 1.21 | |||
| Price | $2.05 | |||
| Enterprise Value/EBITDA (TTM) | -0.23 | |||
| Enterprise Value/EBIT | -0.22 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 587.400K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 320 8200 | |||
| Address | 9955 Mesa Rim Road San Diego, CA 92121 | |||
| Website | biocept.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -552.29% | |||
| Profit Margin | -553.64% | |||
| Management Effectiveness | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -53.53% | |||
| Return on Equity | -- | |||
| Income Statement | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $6.59M | |||
| Total Revenue (TTM) | $6.59M | |||
| Revenue Per Share | $11.21 | |||
| Gross Profit (TTM) | -$14.55M | |||
| EBITDA (TTM) | -$34.66M | |||
| EBIT (TTM) | -$36.37M | |||
| Net Income (TTM) | -$36.46M | |||
| Net Income Avl. to Common (TTM) | -$36.46M | |||
| Total Revenue Growth (Q YOY) | -96.63% | |||
| Earnings Growth (Q YOY) | -223.26% | |||
| EPS Diluted (TTM) | -$64.21 | |||
| EPS Diluted Growth (Q YOY) | -212.60% | |||
| Balance Sheet | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $6.77M | |||
| Cash Per Share (Q) | $11.53 | |||
| Total Current Assets (Q) | $9.09M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $2.43M | |||
| Current Ratio (Q) | 2.070 | |||
| Book Value Per Share (Q) | $4.10 | |||
| Total Assets (Q) | $22.99M | |||
| Total Current Liabilities (Q) | $4.39M | |||
| Total Debt (Q) | $11.58M | |||
| Total Liabilities (Q) | $20.57M | |||
| Total Common Equity (Q) | $2.43M | |||
| Cash Flow | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -$800.00K | |||
| Cash from Financing (TTM) | -$1.44M | |||
| Net Change in Cash (TTM) | -$20.79M | |||
| Levered Free Cash Flow (TTM) | -$13.14M | |||
| Cash from Operations (TTM) | -$18.55M | |||
